Marshall Wace, LLP Novo Cure LTD Transaction History

Marshall Wace, LLP

$74.4 Billion
Q1 2025

A detailed history of Marshall Wace, LLP transactions in Novo Cure LTD stock. As of the latest transaction made, Marshall Wace, LLP holds 1,807,591 shares of NVCR stock, worth $32.9 Million. This represents 0.04% of its overall portfolio holdings.

Number of Shares

1,807,591

Previous 270,952 567.13%

Holding current value

$32.9 Million

Previous $8.07 Million 298.95%

% of portfolio

0.04%

Previous 0.01%

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	BUY	$17.82 - $30.19 $27.4 Million - $46.4 Million	1,536,639 Added 567.13%	1,807,591 $32.2 Million
Q4 2024 Feb 13, 2025	SELL	$14.54 - $33.41 $7.4 Million - $17 Million	-508,718 Reduced 65.25%	270,952 $8.07 Million
Q3 2024 Nov 14, 2024	BUY	$15.61 - $23.34 $4.41 Million - $6.59 Million	282,196 Added 56.73%	779,670 $12.2 Million
Q2 2024 Aug 14, 2024	SELL	$11.83 - $24.05 $3.22 Million - $6.54 Million	-272,053 Reduced 35.35%	497,474 $8.52 Million
Q1 2024 May 15, 2024	BUY	$12.42 - $17.29 $5.24 Million - $7.3 Million	422,099 Added 121.49%	769,527 $12 Million
Q4 2023 Feb 14, 2024	BUY	$11.13 - $15.78 $3.16 Million - $4.48 Million	284,067 Added 448.33%	347,428 $5.19 Million
Q3 2023 Nov 14, 2023	SELL	$16.15 - $42.35 $2.47 Million - $6.49 Million	-153,241 Reduced 70.75%	63,361 $1.02 Million
Q2 2023 Aug 14, 2023	BUY	$40.29 - $82.51 $8.08 Million - $16.5 Million	200,516 Added 1246.52%	216,602 $8.99 Million
Q1 2023 May 15, 2023	BUY	$56.44 - $118.81 $907,893 - $1.91 Million	16,086 New	16,086 $967,000
Q2 2022 Aug 15, 2022	BUY	$56.6 - $89.9 $5.93 Million - $9.42 Million	104,760 New	104,760 $7.28 Million
Q1 2022 May 16, 2022	SELL	$60.15 - $84.52 $214,855 - $301,905	-3,572 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$75.08 - $121.99 $268,185 - $435,748	3,572 New	3,572 $268,000
Q1 2021 May 17, 2021	SELL	$124.11 - $190.17 $366,248 - $561,191	-2,951 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$112.16 - $174.14 $330,984 - $513,887	2,951 New	2,951 $511,000
Q2 2018 Aug 14, 2018	SELL	$19.85 - $32.0 $327,525 - $528,000	-16,500 Closed	0 $0
Q1 2018 May 15, 2018	BUY	$19.3 - $23.65 $318,450 - $390,225	16,500 New	16,500 $360,000

Others Institutions Holding NVCR

# of Institutions

266

Shares Held

79.4M

Call Options Held

970K

Put Options Held

118K

View Full List

About NovoCure Ltd

Ticker NVCR
Exchange NASDAQ
Sector Healthcare
Industry Medical Instruments & Supplies
Shares Outstandng 104,950,000
Market Cap $1.91B
Description
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optu...

More about NVCR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Marshall Wace, LLP with notifications on news.

Account

Marshall Wace, LLP Novo Cure LTD Transaction History